Art. -Nr.: HY-11108

R406 free base

37 Cited Publications

Kundenbewertung

Based on 37 publication(s) in Google Scholar

R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 free base reduces immune complex-mediated inflammation. R406 free base also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.07%
CAS. Nr.: 841290-80-0
Formel: C₂₂H₂₃FN₆O₅
Molecular Weight:470.45

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

R406 free base Chemical Structure

CAS. Nr.: 841290-80-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (37)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 free base reduces immune complex-mediated inflammation^[1]. R406 free base also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM)^[2].

IC₅₀ & Target

Ki: 30 nM (Syk)^[1]
IC50: 41 nM (Syk)^[1]
FLT3^[1]
IC50: 63 nM (Lyn), 37 nM (Lck)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
B-cell	EC₅₀	48 nM Compound: 3, R406	Inhibition of SYK in human B-cells cells assessed as reduction in FcepsilonR1/FcgammaR-mediated signaling responses Inhibition of SYK in human B-cells cells assessed as reduction in FcepsilonR1/FcgammaR-mediated signaling responses	[PMID: 22257213]
Bone marrow cell	IC₅₀	147 nM Compound: 2	Inhibition of IL3 dependent proliferation in C57/B16 mouse bone marrow cells using [3H]thymidine by liquid scintillation counting Inhibition of IL3 dependent proliferation in C57/B16 mouse bone marrow cells using [3H]thymidine by liquid scintillation counting	[PMID: 24726806]
HUVEC	EC₅₀	36 nM Compound: 1, R406	Inhibition of KDR in VEGF-stimulated HUVEC assessed as phosphorylation after 1 hr incubation Inhibition of KDR in VEGF-stimulated HUVEC assessed as phosphorylation after 1 hr incubation	[PMID: 24779514]
MV4-11	EC₅₀	10 nM Compound: 1, R406	Inhibition of Flt3 in human MV411 cells assessed as assessed as proliferation after 72 hrs incubation by spectrophotometry Inhibition of Flt3 in human MV411 cells assessed as assessed as proliferation after 72 hrs incubation by spectrophotometry	[PMID: 24779514]
Ramos	EC₅₀	53 nM Compound: 1, R406	Inhibition of Syk in antihuman IgM-stimulated human Ramos cells assessed as decrease in BCR-mediated BLNK phosphorylation by cellular assay Inhibition of Syk in antihuman IgM-stimulated human Ramos cells assessed as decrease in BCR-mediated BLNK phosphorylation by cellular assay	[PMID: 24779514]
Ramos	IC₅₀	457 nM Compound: 2	Inhibition of Syk in anti IgM-stimulated human Ramos cells assessed as BLNK phosphorylation by cellular assay Inhibition of Syk in anti IgM-stimulated human Ramos cells assessed as BLNK phosphorylation by cellular assay	[PMID: 24726806]
SK-N-SH	EC₅₀	80 nM Compound: 3, R406	Inhibition of Ret in human SK-N-SH cells Inhibition of Ret in human SK-N-SH cells	[PMID: 22257213]
TF-1	EC₅₀	13 nM Compound: 1, R406	Inhibition of Jak2 in erythropoietin-stimulated human TF1 cells assessed as assessed as phospho-Stat5 after 1 hr incubation Inhibition of Jak2 in erythropoietin-stimulated human TF1 cells assessed as assessed as phospho-Stat5 after 1 hr incubation	[PMID: 24779514]
THP-1	EC₅₀	171 nM Compound: 3, R406	Inhibition of SYK in human THP1 cells assessed as reduction in FcepsilonR1/FcgammaR-mediated signaling responses Inhibition of SYK in human THP1 cells assessed as reduction in FcepsilonR1/FcgammaR-mediated signaling responses	[PMID: 22257213]

In Vitro

R406 inhibits adenosine A3 receptor (IC₅₀=0.081 μM), adenosine transporter (IC₅₀=1.84 μM), and monoamine transporter (IC₅₀=2.74 μM)^[1].
R406 inhibits Huh7 hepatocyte, A549 epithelial, and H1299 lung cancer lines with EC₅₀s of 15.1, 2.9 and 6.3 μM, respectively^[1].
R406 inhibits phosphorylation of Syk substrate LAT in mast cells and BLNK/SLP65 in B cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Cultured human mast cells (CHMC)
Concentration:

0.016, 0.08, 0.4, 2 µM
Incubation Time:

40 minutes
Result:

Inhibited all other kinases tested at 5 to 100 fold less potency than Syk as judged by phosphorylation of target proteins.

In Vivo

R406 (5 and 10 mg/kg) shows efficacy in the amelioration of the Arthus reaction and in reducing clinical symptoms in the collagen antibody-induced arthritis (CAIA) and K/BxN models of rheumatoid arthritis (RA). Immune complex (IC)-mediated inflammation is reduced by inhibition of Fc receptor signaling with R406^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Balb/c mice (6-8 weeks) with CAIA^[1]
Dosage:

5 and 10 mg/kg
Administration:

Administered orally, b.i.d, for 14 days, starting 4 hours after antibody challenge on day 0.
Result:

Reduced inflammation and swelling, and the arthritis progressed more slowly in treated animals than in vehicle controls.

Animal Model:

Female C57BL/6 mice with arthritis^[1]
Dosage:

10 mg/kg
Administration:

Administered orally one hour before serum injection; b.i.d; for 13 days
Result:

Delayed the onset and reduced the severity of clinical arthritis. Paw thickening and clinical arthritis were reduced by approximately 50%.

Chemical Information

CAS. Nr. 841290-80-0
Appearance Solid
Molecular Weight 470.45
Formel C₂₂H₂₃FN₆O₅
Color White to light yellow
SMILES

COC1=CC(NC2=NC(NC3=NC(N4)=C(C=C3)OC(C)(C)C4=O)=C(C=N2)F)=CC(OC)=C1OC
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (37)

All Cell Migration/Invasion AssayWBFlow CytometryIP

Sort by:

Journal Impact Factor

Nature

Inhibitors supercharge kinase turnover through native proteolytic circuits. [Abstract]

2026 Jan;649(8098):1032-1041. PMID: 41299171
Cell

Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. [Abstract]

2018 Oct 4;175(2):442-457.e23. PMID: 30290143

R406 free base purchased from MedChemExpress. Usage Cited in: Cell. 2018 Oct 4;175(2):442-457.e23. [Abstract]

Syk inhibitors (R406 (5 μM) and Piceatannol) are added during the induction of trastuzumab-dependent BT-474 phagocytosis. The binding of the phagosome marker Rab7 to AIM2 in macrophages are evaluated by co-immunoprecipitation.
Adv Mater

Glycocalyx-Mimicking Nanoparticles with Differential Organ Selectivity for Drug Delivery and Therapy. [Abstract]

2024 Mar 15:e2311283. PMID: 38489768
Nat Commun

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. [Abstract]

2022 Apr 19;13(1):2136. PMID: 35440579

R406 free base purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Apr 19;13(1):2136. [Abstract]

Comparison of pharmacological inhibitors with the corresponding guides of positive and negative controls for BCR-controlled adhesion. Top plots: Namalwa cells pretreated with 100 nM ibrutinib (BTK inhibitor), 1 μM R406 (Fostamatinib, SYK inhibitor, 1 ), 100 nM wortmannin (pan-PI3K inhibitor), 50 μM PD-98059 (MEK1/2 inhibitor), 2.5 μM MK-2206 (AKT1/2/3 inhibitor), or DMSO control, were stimulated with αIgM or PMA, and allowed to adhere to fibronectin-coated surfaces. Bar graphs are presented as normalized mean + SEM (100% = untreated αIgM-stimulated cells). Bottom plots: MA plots of αIgM-induced adhesion relative to PMA-induced adhesion; the guides of the corresponding genes targeted by the inhibitors of the top plots are highlighted.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Exp Hematol Oncol

Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis. [Abstract]

2022 Nov 8;11(1):88. PMID: 36348389

R406 free base purchased from MedChemExpress. Usage Cited in: Exp Hematol Oncol. 2022 Nov 8;11(1):88. [Abstract]

R406 (1-2 μM; 18-24 h) markedly inhibited C. tropicalis-induced PKM2 Tyr105 phosphorylation and PKM2 nuclear translocation in MDSCs by suppressing Syk.
Theranostics

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. [Abstract]

2021 May 24;11(15):7308-7321. PMID: 34158852

R406 free base purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 May 24;11(15):7308-7321. [Abstract]

The induction of IL-21 secretion by CBP-12-OVA was inhibited by R406, an inhibitor of Syk phosphorylation. FL-DCs were incubated with 2.5 µM R406 for 1 h, and then cultured with 100 µg/mL of the indicated peptides for 6 h at 37 °C. IL-21 positive frequency was determined by ICS assay.
J Adv Res

METTL3 promotes neutrophil extracellular trap formation via SYK/ERK/MEK signaling during acute lung injury. [Abstract]

2026 Jan 22:S2090-1232(26)00069-X. PMID: 41579954
Redox Biol

HDAC11 negatively regulates antifungal immunity by inhibiting Nos2 expression via binding with transcriptional repressor STAT3. [Abstract]

2022 Oct:56:102461. PMID: 36087429
Arthritis Rheumatol

Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. [Abstract]

2018 Sep;70(9):1419-1428. PMID: 29669391
Cell Rep Med

MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1. [Abstract]

2025 Jan 16:101922. PMID: 39842432
Mater Today Bio

A dual-targeting therapeutic nanobubble for imaging-guided atherosclerosis treatment. [Abstract]

2024 Mar 22:26:101037. PMID: 38586870
J Neuroinflammation

Metformin attenuates central sensitization by regulating neuroinflammation through the TREM2-SYK signaling pathway in a mouse model of chronic migraine. [Abstract]

2024 Dec 3;21(1):318. PMID: 39627853
Cell Death Dis

Activation of AKT via a dual mechanism enhances the susceptibility of melanoma cells to glucose deprivation. [Abstract]

2025 Aug 7;16(1):595. PMID: 40774947
Cell Commun Signal

Mitochondria-mediated ferroptosis induced by CARD9 ablation prevents MDSCs-dependent antifungal immunity. [Abstract]

2024 Apr 2;22(1):210. PMID: 38566195
Blood Adv

Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation. [Abstract]

2024 Nov 12;8(21):5653-5662. PMID: 39265169
Cell Rep

Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity. [Abstract]

2023 Mar 20;42(3):112275. PMID: 36943864
Atherosclerosis

Inhibition of vascular neointima hyperplasia by FGF21 associated with FGFR1/Syk/NLRP3 inflammasome pathway in diabetic mice. [Abstract]

2019 Oct;289:132-142. PMID: 31513948
Front Pharmacol

Inhibition of Spleen Tyrosine Kinase Restores Glucocorticoid Sensitivity to Improve Steroid-Resistant Asthma. [Abstract]

2022 May 5;13:885053. PMID: 35600871
iScience

Decoding sunitinib resistance in ccRCC: Metabolic-reprogramming-induced ABAT and GABAergic system shifts. [Abstract]

2024 Jun 28;27(7):110415. PMID: 39100925
iScience

SWI/SNF complex-mediated chromatin remodeling in Candida glabrata promotes immune evasion. [Abstract]

2024 Mar 27;27(4):109607. PMID: 38632999
iScience

Heat-killed Mycobacterium tuberculosis induces trained immunity in vitro and in vivo administered systemically or intranasally. [Abstract]

2024 Jan 11;27(2):108869. PMID: 38318361
J Biol Chem

Aspartyl proteases in Candida glabrata are required for suppression of the host innate immune response. [Abstract]

2018 Apr 27;293(17):6410-6433. PMID: 29491142
ACS Infect Dis

Coordinated Regulation of TLR2 Signaling by Neu1 Sialidase and the Siglec-5/Siglec-14 Receptor Pair During Mycoplasma pneumoniae Infection. [Abstract]

2026 Jun 25. PMID: 42350323
ACS Infect Dis

Sialylated Lipooligosaccharide Contributes to Glaesserella parasuis Penetration of Porcine Respiratory Epithelial Barrier. [Abstract]

2021 Mar 12;7(3):661-671. PMID: 33645216
Life Metab

Intermittent fasting inhibits platelet activation and thrombosis through the intestinal metabolite indole-3-propionate. [Abstract]

2025 Jan 29;4(2):loaf002. PMID: 40078933
Mol Immunol

Tanshinone I limits inflammasome activation of macrophage via docking into Syk to alleviate DSS-induced colitis in mice. [Abstract]

2024 Jul 31:173:88-98. PMID: 39088935
J Pharmacol Sci

Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice. [Abstract]

2017 May;134(1):29-36. PMID: 28479222

R406 free base purchased from MedChemExpress. Usage Cited in: J Pharmacol Sci. 2017 May;134(1):29-36. [Abstract]

The effects of R406 treatment on the phosphorylation of 3BP2 and p38MAPK in white blood cells from the spleens of NZB/W F1 mice. (A) The phosphorylation of the 3BP2 and (B) the phosphorylation of p38MAPK in the renal cortex of control and R406-treated mice.
BMC Cardiovasc Disord

Sodium tanshinone IIA sulfonate protects vascular relaxation in ApoE-knockout mice by inhibiting the SYK-NLRP3 inflammasome-MMP2/9 pathway. [Abstract]

2024 Jul 12;24(1):354. PMID: 38992615
Scand J Immunol

Isoliquiritigenin limits inflammasome activation of macrophage via docking into Syk to alleviate murine non-alcoholic fatty liver disease. [Abstract]

2024 Apr 26:e13371. PMID: 38671579
SSRN

2025 Dec 2.
Stony Brook University

2025.
bioRxiv

2024 Apr 9.
SSRN

2023 Jun 29.
bioRxiv

2022 Dec 21, 519945.
Ann Transl Med

Upregulated miR-155 inhibits inflammatory response induced by C. albicans in human monocytes derived dendritic cells via targeting p65 and BCL-10. [Abstract]

2019 Dec;7(23):758. PMID: 32042774
Nihon University

School of Medicine. 2014 Mar.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (53.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1256 mL

10.6281 mL

21.2562 mL

5 mM

0.4251 mL

2.1256 mL

4.2512 mL

10 mM

0.2126 mL

1.0628 mL

2.1256 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.31 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sylvia Braselmann, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. [Content Brief]

[2]. Hoon-Suk Cha , et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317(2):571-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1256 mL	10.6281 mL	21.2562 mL	53.1406 mL
	5 mM	0.4251 mL	2.1256 mL	4.2512 mL	10.6281 mL
	10 mM	0.2126 mL	1.0628 mL	2.1256 mL	5.3141 mL
	15 mM	0.1417 mL	0.7085 mL	1.4171 mL	3.5427 mL
	20 mM	0.1063 mL	0.5314 mL	1.0628 mL	2.6570 mL
	25 mM	0.0850 mL	0.4251 mL	0.8502 mL	2.1256 mL
	30 mM	0.0709 mL	0.3543 mL	0.7085 mL	1.7714 mL
	40 mM	0.0531 mL	0.2657 mL	0.5314 mL	1.3285 mL
	50 mM	0.0425 mL	0.2126 mL	0.4251 mL	1.0628 mL

Keywords

R406 free base

37 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

R406 free base

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Anti-diabetic Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) R406 free base

Biologische Aktivität

Chemical Information

Publications (37)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

R406 free base

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Anti-diabetic Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) R406 free base

Biologische Aktivität

Chemical Information

Publications (37)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

R406 free base Related Classifications

HY-11108 Related Classifications